Literature DB >> 10705014

Treatment of superficial esophageal cancer by external radiation therapy alone: results of a multi-institutional experience.

K Nemoto1, Y Matsumoto, M Yamakawa, S Jo, Y Ito, M Oguchi, N Kokubo, Y Nishimura, S Yamada, T Okawa.   

Abstract

PURPOSE: To assess the effectiveness and toxicity of external radiation therapy for superficial esophageal cancer. METHODS AND MATERIALS: During the period from March 1979 to November 1996, 78 patients with superficial esophageal cancer received radiation therapy without intracavitary irradiation at nine radiotherapy institutions in Japan. All patients had histologically-proven squamous cell carcinoma. Endoscopic ultrasonography was performed in 34 patients to discriminate mucosal from submucosal cancer. Most of the patients had received radiation therapy using conventional fractionation at an average dose of 65.5 Gy.
RESULTS: The survival rates at 1, 2, and 5 years were 88%, 73%, and 45%, respectively. The local control rates at 1, 2, and 5 years were 85%, 79%, and 66%, respectively. Although the difference was not significant, the survival rate of cancer patients with a tumor invading the submucosa was lower than that of the other patients. In 6 mucosal cancer patients, local recurrence was observed in 1 patient with extensive cancer. Regional lymph node recurrence and distant failure were not observed in mucosal cancer patients, while in 28 submucosal cancer patients, the 5-year survival rate and relapse free rate were only 49% and 43%, respectively. Univariate and multivariate analysis identified age as the only significant prognostic factor. Severe late injury, such as esophageal ulcer, perforation, and bleeding, was not observed.
CONCLUSION: External radiation therapy is effective for mucosal cancer. However, further investigation is needed to establish a better standard treatment protocol for submucosal cancer.

Entities:  

Mesh:

Year:  2000        PMID: 10705014     DOI: 10.1016/s0360-3016(99)00485-x

Source DB:  PubMed          Journal:  Int J Radiat Oncol Biol Phys        ISSN: 0360-3016            Impact factor:   7.038


  6 in total

1.  Clinical outcomes of radiotherapy for esophageal cancer between 2004 and 2008: the second survey of the Japanese Radiation Oncology Study Group (JROSG).

Authors:  Yasumasa Nishimura; Keiichi Jingu; Satoshi Itasaka; Yoshiharu Negoro; Yuji Murakami; Katsuyuki Karasawa; Gen Kawaguchi; Fumiaki Isohashi; Masao Kobayashi; Yoshiyuki Itoh; Takuro Ariga
Journal:  Int J Clin Oncol       Date:  2015-07-16       Impact factor: 3.402

2.  Current status of radiotherapy for patients with thoracic esophageal cancer in Japan, based on the Comprehensive Registry of Esophageal Cancer in Japan from 2009 to 2011 by the Japan Esophageal Society.

Authors:  Yasushi Toh; Hodaka Numasaki; Yuji Tachimori; Takashi Uno; Keiichi Jingu; Kenji Nemoto; Hisahiro Matsubara
Journal:  Esophagus       Date:  2019-08-31       Impact factor: 4.230

3.  Clinical practice and outcome of radiotherapy for esophageal cancer between 1999 and 2003: the Japanese Radiation Oncology Study Group (JROSG) Survey.

Authors:  Yasumasa Nishimura; Ryuta Koike; Kazuhiko Ogawa; Ryuta Sasamoto; Yuji Murakami; Yoshiyuki Itoh; Yoshiharu Negoro; Satoshi Itasaka; Toru Sakayauchi; Tetsuro Tamamoto
Journal:  Int J Clin Oncol       Date:  2011-05-25       Impact factor: 3.402

4.  The Importance of Concurrent Chemotherapy for T1 Esophageal Cancer: Role of FDG-PET/CT for Local Control.

Authors:  Ichiro Ogino; Shigenobu Watanabe; Kingo Hirasawa; Toshihoro Misumi; Masaharu Hata; Chikara Kunisaki
Journal:  In Vivo       Date:  2018 Sep-Oct       Impact factor: 2.155

Review 5.  Prevention and management of early esophageal cancer.

Authors:  W Michael Korn
Journal:  Curr Treat Options Oncol       Date:  2004-10

6.  Clinical results of proton beam therapy for twenty older patients with esophageal cancer.

Authors:  Takashi Ono; Tatsuya Nakamura; Yusuke Azami; Hisashi Yamaguchi; Yuichiro Hayashi; Motohisa Suzuki; Yoshiomi Hatayama; Iwao Tsukiyama; Masato Hareyama; Yasuhiro Kikuchi; Kenji Nemoto
Journal:  Radiol Oncol       Date:  2015-11-27       Impact factor: 2.991

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.